CCL19/MIP-3 beta Antibody (OTI2A12) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-71278IR
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI2A12
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant protein fragment corresponding to amino acids 22-98 of human CCL19/MIP-3 beta (NP_006265) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for CCL19/MIP-3 beta Antibody (OTI2A12) [DyLight 755]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CCL19/MIP-3 beta
Alternate Names
ELC, MIP-3 beta, MIP3 beta
Gene Symbol
CCL19
Additional CCL19/MIP-3 beta Products
Product Documents for CCL19/MIP-3 beta Antibody (OTI2A12) [DyLight 755]
Product Specific Notices for CCL19/MIP-3 beta Antibody (OTI2A12) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...